Shuji Terai

Professor and Chairman

Niigata University

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Shuji Terai is a Professor and Chairman at Niigata University, Japan. His research interests include viral hepatitis, hepatic fibrosis, diabetes management, and liver cancer, as evidenced by his recent publications. His work focuses on the implications of novel therapies and diagnostic techniques in liver-related diseases, contributing valuable insights to the fields of hepatology and endocrinology.

Articles (15)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (9)

Tatsunori Hanai

Gifu University

JAPAN

View details

Akihiko Saitoh

Niigata University Graduate School of Medical and Dental Sciences

JAPAN

View details

Kenya Kamimura

Niigata University

JAPAN

View details

Tatsuo Kanda

Professor

Niigata University Medical and Dental Hospital

JAPAN

View details

Hiroaki Okamoto

Professor

Jichi Medical University

JAPAN

View details

Yasuhiro Takikawa

JAPAN

View details

Atsushi Tanaka

JAPAN

View details

Takeshi Yokoo

Niigata University

JAPAN

View details

Hirofumi Kogure

Nihon University School of Medicine

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Shuji Terai

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Zinc Acetate Inhibits Hepatitis A Virus Replication: Possible Treatment for Patients with Type A Acute-on-Chronic Liver Failure

Revisiting Hepatic Fibrosis Risk in Congenital Heart Disease: Insights from Non-Invasive Markers and Echocardiography

Simultaneous Evaluation of Shear Wave Elastography and C-Peptide Index for Predicting Need of Insulin Therapy in Type 2 Diabetes: A Pilot Study

Correction: Watanabe et al. Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. <i>Livers</i> 2023, <i>3</i>, 562–568

BCL11B expression in hepatocellular carcinoma relates to chemosensitivity and clinical prognosis

Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17β-hydroxysteroid dehydrogenase 13 expression

Cell‐free and concentrated ascites reinfusion therapy versus large‐volume paracentesis for the treatment of cirrhotic patients with refractory ascites: A multicenter prospective observational study

Analysis of Genetic Relatedness between Gastric and Oral <em>Helicobacter pylori</em> in Patients with Early Gastric Cancer Using Multilocus Sequence Typing

Analysis of drug-induced liver-related adverse event trend reporting between 1997 and 2019

Early-phase prothrombin time-international normalized ratio in acute liver injury indicates the timing of therapeutic intervention and predicts prognostic improvement

Escherichia coli-derived outer-membrane vesicles induce immune activation and progression of cirrhosis in mice and humans

Machine learning prediction model for treatment responders in patients with primary biliary cholangitis

Navitoclax improves acute-on-chronic liver failure by eliminating senescent cells in mice

Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4-sclerosing cholangitis: Based on a Japanese nationwide study

Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect

Collaborators (9)

Tatsunori Hanai

Akihiko Saitoh

Kenya Kamimura

Tatsuo Kanda

Hiroaki Okamoto

Yasuhiro Takikawa

Atsushi Tanaka

Takeshi Yokoo

Hirofumi Kogure

Make your next move.